151 results about "Ornithine synthesis" patented technology

A method of characterizing a multi-component mixture for use in a bioprocess operation that includes providing a multi-component mixture standard with pre-determined amounts of known components; performing a Raman Spectroscopy analysis on the multi-component mixture standard; providing a multi-component test mixture from the bioprocess operation; performing a Raman Spectroscopy analysis on the multi-component test mixture; and comparing the analysis of the multi-component mixture standard and the multi-component test mixture to characterize the multi-component test mixture. In one embodiment, the multi-component mixture standard and the multi-component test mixture both comprise one or more of, at least two, at least three of, or each of, a polysaccharide (e.g. sucrose or mannitol), an amino acid (e.g., L-arginine, L-histidine or L-ornithine), a surfactant (e.g. polysorbate 80) and a pH buffer (e.g., a citrate formulation).

The present invention relates to the use of zinc complexes of natural amino acids, especially L-arginine, L-lysine, L-ornithine, and other natural amino acids, in a molar ratio of about 1:2 (metal:amino acid), and formulations thereof. These pharmaceutical compositions offer better tolerated and faster acting regimens than common zinc salts (i.e., acetate, sulfate, etc.) for long term maintenance therapy of diseases caused by abnormal elevated copper levels, such as in Wilson's disease, inflammatory and fibrotic diseases and Alzheimer's disease.

The diet food of this invention having effects to reduce body weight and prevent / improve obesity and atherosclerotic or metabolic disorders includes an ω-3 PUFA or an ω-6 PUFA, and at least one of L-arginine, L-ornithine, an L-arginine precursor and an L-ornithine precursor, and further includes diacylglycerol, a middle or short chain fatty acid, a phytosterol, a nucleo-base, a nucleoside, a nucleic acid, dextrin, various vitamins, various minerals or a probiotics material.

Disclosed herein are crystalline forms of L-ornithine phenyl acetate and methods of making the same. The crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.

The invention belongs to the field of medical health products, and in particular relates to a pharmaceutical composition for promoting nerve injury restoration and an application thereof. The pharmaceutical composition in each unit contains 0.5-8g of L-ornithine, 1-5g of aspartic acid, 3-10g of arginine, 3-10g of vitamin B6, and the balance of accessories and / or other components. The pharmaceutical composition disclosed by the invention can obviously promote the restoration of spinal nerve function, and can be used for preparing medicines of nerve injury restoration; and the pharmaceutical composition has very good curative effect on avute myelitis.

The invention belongs to the field of biological pharmaceutics, and discloses a method for separating and purifying L-ornithine by using a simulated moving bed. The method comprises the following steps: firstly, removing bacteria and solid substances from L-ornithine fermentation solution by using ultra-filtration; secondly, feeding the solution into the simulated moving bed, adsorbing the solution, washing the impurities, eluting the L-ornithine, collecting the elution and regenerating a column; and finally, concentrating and decolorizing the collected elution, adjusting the pH of the elution to between 4.5 and 5.0 with hydrochloric acid, crystallizing the elution, and drying the crystal to obtain L-ornithine hydrochloride crystal. The L-ornithine separated and purified by using the method has the advantages of high yield, high purity, low cost, environmental protection, and suitability for industrialized production.

The invention belongs to the field of fermentation engineering and discloses corynebacterium glutamicum and a method for preparing L-ornithine and salts thereof by using the same. The corynebacterium glutamicum is corynebacterium glutamicum 1006 with the collection number of CGMCCNo.3663. The method comprises the following steps of: culturing the corynebacterium glutamicum in a culture medium containing carbon sources, nitrogen sources and inorganic salts at the temperature of between 28 and 30 DEG C to generate L-ornithine fermentation liquor; removing the thalli of the fermentation liquor by using ceramic membranes of 1 to 15 ten thousand Dalton; separating the fermentation liquor by using cation exchange resins to obtain L-ornithine solution; and decoloring and crystallizing the L-ornithine solution by a hydrochloric acid and ethanol method to obtain L-ornithine hydrochloride. The method has the advantages of simple thallus cultivation and contribution to industrialized mass production. The accumulation of the L-ornithine prepared from the corynebacterium glutamicum reaches 35 to 45g / L.

The invention provides a method for producing L-ornithine by microbial fermentation, namely, using Corynebacterium glutamate to obtain the strains of CS-189(cit<(-)>+SG<r>) by chemical treatment, and obtain the L-ornithine hydrochloride by fermentation, culture solution micro-filtration by a ceramic membrane, ion exchange resin and extraction by a hydrothermal crystallization method with decompression concentration. The strains used in the method are auxotrophy resistant to sulfaguanidine, which significantly enhances acid yield by fermentation. Meanwhile, aiming at the problem that the solubility of the L-ornithine hydrochloride in water is extremely difficult, the hydrothermal crystallization method is adopted to obtain better extraction rate under the condition that flammable and explosive alcohol is not used. The method simplifies processes and reduces extraction cost.

Disclosed herein are methods of treating and preventing muscle loss using ornithine in combination with at least one of phenyl acetate and phenylbutyrate.

The invention discloses a method for producing L-ornithine hydrochloride through weak Ba(OH)2 hydrolysis L-arginine hydrochloric salts, neutralizing with dilute sulfuric acid, removing Ba2+, obtaining L-ornithine hydrochloride crystallized crude product through concentrated crystallization, re-crystallizing in pure water to obtain the pure product.

the invention discloses a preparing method of L-ornithine, which comprises the following steps: preparing inclined-plane seed; selecting culture medium; optimizing converting condition; extracting product. the invention improves converting rate of arginine by 99.5%, which provides basic raw material for medical industry.

The invention belongs to a yellow wine brewing method, which comprises the steps of rice soaking, rice steaming, water spraying, jar falling and pot erecting, yeast and water addition, fermentation and post treatment, wherein L-ornithine monohydrochloride is added into fermentation liquid in the second day to the six day after the jar falling and pot erecting. The yellow wine brewing method has the advantages that the L-ornithine monohydrochloride as an inhibitor is easy to control, the inhibition efficiency is high, and the generation of ethyl carbamate can be effectively inhibited; after the L-ornithine monohydrochloride is dissolved in water, ornithine is generated and participates in uric acid circulation in vivo, no risk and no toxic and harm exist, and no environment pollution is caused; and in addition, the L-ornithine monohydrochloride is easy to obtain, the use is convenient, and the cost is low.

The invention belongs to the field of pharmaceutical chemical engineering, and discloses a L-ornithine lipoic acid compound salt, and a preparation method and application thereof. A structural formula of the L-ornithine lipoic acid compound salt is as shown in the formula I. The L-ornithine lipoic acid compound salt has functions of preventing and treating hepatic coma caused by acute and chronic hepatic diseases such as liver cirrhosis, fatty liver, hepatitis and the like and can be used for preparing a medicament for treating hepatic coma. The preparation method for the L-ornithine lipoic acid compound salt is simple and easy to operate and is low in cost; the product is high in purity.

The invention relates to an ornithine aspartate compound and a novel method thereof. L-aspartic acid and L-ornithine acetate are used as starting materials. The method comprises the following steps of: removing ammonium acetate serving as an intermediate product through solubility differences of ornithine and the ammonium acetate in acetone to obtain free alkali of the ornithine; and reacting thefree alkali with the L-aspartic acid to generate the ornithine and aspartate compound. The synthetic method of the ornithine and aspartate compound has the advantages of low cost, simple process, high purity of the obtained product and easy industrial production.

The invention discloses a composite (B) for disintoxicating and sobering, which is prepared by glucose and fructose, fruit glucose, honey, L-cysteine, L-alanine, L-ornithine, L-glutamine, L-carnitine according to a certain weight range. In order to enable the effect better, one or more of taurine, L-asparaginic acid or L-aspartate, vitamin B1, vitamin B6, caffeine, L-arginine, L-glutamic acid, L-proline, phaseomannite, vitamin B2, nicotinic acid, folic acid, vitamin B12 and pantothenic acid are also added. The composite can be prepared into liquid preparation and electuary. The composite of the invention can be prepared into food and health food. The invention can quickly disintoxicate, sober, eliminate alcoholism symptom and continued effect of alcohol on a human body, and has no side effect.

The invention discloses a method for producing L-ornithine hydrochloride by TOP10 / PBAD / Thio-TOPO-Arg-Bsub colibacillus genetic engineering bacteria. The strain can express and generate excess bacillus subtilis arginase, and efficiently converts L-arginine into L-ornithine.

The invention relates to a preparation method of L-ornithine-L-aspartate, which comprises the following steps: mixing L-ornithine hydrochloride and deionized water; adding anion exchange resin and continue stirring to obtain a mixed solution; detecting chloride ion content by utilizing a silver nitrate solution; then adding aspartate; removing the resin and concentrating the filtrate after stirring reaction is ended; adding activated carbon for decoloration and dropwise adding absolute ethyl alcohol; then cooling the decolorized filtrate to the room temperature for separating out crystal; and drying the obtained crystal for 8-30h after the filtering is ended. Compared with the prior art, the preparation method does not generate exhaust gas or waste residues, generates low amount of waste water, basically does not need COD (chemical oxygen demand) and BOD (biochemical oxygen demand), almost does not pollute the environment and has high total product yield which can reach more than 80 percent, does not use poisonous raw materials and has higher product quality.

The invention relates to sodium-alginate-based hydrogel and a preparation method thereof. The sodium-alginate-based hydrogel is prepared through steps as follows: 1) 100-300 mg of aminated sodium alginate, 20-100 mg of L-lysine or 25-120 mg of L-arginine or 18-90 mg of L-ornithine and 20-100 mg of nano ferroferric oxide magnetic particles are dissolved in a PBS solution; 2) 50-300 mg of oxidized sodium alginate is dissolved in a borax solution; 3) solutions obtained in steps 1) and 2) are mixed and stirred and react at the constant temperature of 25-40 DEG C for 0.5-24 h, and the sodium-alginate-based hydrogel is obtained. Oxidized sodium alginate is prepared by reacting sodium alginate with an oxidizing agent under the acid condition, and aminated sodium alginate is prepared by modifying sodium alginate with a diamine compounds. The prepared sodium-alginate-based hydrogel has the advantages of being injectable, self-healing, degradable, good in biocompatibility and the like, raw material sources are wide, the preparation process is simple, and industrial production is facilitated.

It is intended to provide a polypeptide having (i) an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO:1 by substitution of one or more amino acids in the amino acid sequences of from the 20- to the 38-th positions from the N end, or (ii) an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO:1 by substitution of one or more amino acids in the amino acid sequences of from the 20- to the 38-th positions from the N end and deletion, substitution or addition of one or more amino acids in the amino acid sequence of from the first to the 19-th positions or from the 39-th to the 294-th positions, and having an N-acetylglutamate kinase activity.

The invention provides a metabolic transformation strategy for efficiently improving production capacity of corynebacterium crenatum SYPA5-5 L-arginine, and belongs to the biological technical field. Histidine at a site 268 in N-acetyl glutamatekinase, NAGK, argB of SYPA-5 is mutated into asparaginate, so that feedback inhibition effect of the L-arginine on NAGK can be effectively relived; a mutation site is precisely introduced to a corresponding position of SYPA5-5 genome, so that yield of the obtained feedback inhibition-preventing bacterial strain (H-7)L-arginine is lowered, and metabolic intermediate (L-ornithine and L-citrulline) is largely accumulated. Transcriptional analysis is carried out on an arg gene cluster of h-7 to find that arg GH transcriptional level is lowered. Arg GH reinforced expression is carried out in H-7, and production capacity of the obtained recombinant bacterial strain H-7-GH, L-arginine is improved by 99.0% in comparison with SYPA5-5. Preliminary optimization is carried out on a fermentation culture medium of H-7-GH, so that yield of the L-arginine is 45.1g / L, which is improved by 49.8% in comparison with that before optimization, and improved by 1.13 times in comparison with SYPA5-5. Feedback inhibition of the L-arginine on NAGK is relieved, and metabolic transformation strategy of the arg GH gene is expressed in a strengthened manner at the same time, so that production capacity of the L-arginine of the SYPA 5-5 is effectively improved.

As a drug for treatment of liver diseases, ornithine aspartate has very wide application clinically. However, existing ornithine aspartate preparation methods consist of: taking ornithine hydrochloride as the raw material, using ion exchange resin to remove chloride ions, then employing ammonia water to conduct elution, carrying out heating to remove ammonia, and adding aspartic acid to perform salification, and have the disadvantages of great time consumption, high cost, large acid-base consumption, great pollution, instability of L-ornithine under an alkaline condition during heating for ammonia removing, and easy generation of impurities. The method provided in the invention includes: adopting ornithine hydrochloride as the starting material, employing an electrodialysis method and making use of the principle that charged ions move under a current function to remove chloride ions in the ornithine hydrochloride, adding aspartic acid to perform salification, and conducting refining with methanol or ethanol. The method not only guarantees the stability of L-ornithine, has the characteristics of simplicity, practicability, and low cost, but also substantially alleviates the environmental protection pressure due to less acid-base consumption, and improves the production capability, thus being suitable for scale-up production.

A process for preparing L-ornithine hydrochloride includes dissolving L-arginine in water, adding crown ether and calcium hydroxide, stirring while heating, adding choline, reaction, cooling, using sulfuric acid to regulate pH value, filtering to remove calcium sulfate, vacuum concentrating, using saturated solution of barium hydroxide to regulate pH value, filtering to remove barium sulfate, using hydrochloric acid to regulate pH value, vacuum concentrating, adding alcohol, cooling and filtering. It has high output rate and purity.

The invention describes a construction method of arginase production engineering bacteria and application of the arginase production engineering bacteria in production of L-ornithine by transformation of L-arginine, and belongs to the technical field of biological engineering. According to the method, by means of molecular biology, thermophilic bacteria Bacillus caldovelox (DSM411) is cloned to obtain arginase gene, a constructed expression plasmid is transfected into E.coli BL21 (DE3), and expression vector high-copy recombine ant arginase-containing engineering bacteria pET28a-ARG is obtained by kanamycin resistance plate screening. The enzyme can still show high activity after induced expression in E.coli. The bacteria obtained by fermentation can be directly used for transformation without breaking, in the condition of 60 DEG C, the engineering bacteria has higher permeability, and is more conducive to the substrate uptake and product release, the reaction speed is greatly improved, the transformation period is only 2-4h, the ornithine yield can reach 120.1g / L, and the transformation rate is 98.9%.

This application relates to the production and characterization of a mutant strain of Aspergillus fumigatus. The application also relates to a method for inhibiting siderophore biosynthesis in Aspergillus fumigatus and an assay for identifying drug candidates or other agents having potential inhibitory activity. The method may comprise, for example, the step of inhibiting an enzyme catalyzing siderophore biosynthesis, such as L-ornithine N5-oxygenase. In one embodiment the siderophore is a hydroxamate siderophore, such as N′N″N′″-triacetylfusarinine C (TAF) or ferricrocin. A method of preventing or treating fungal infections in a patient is also described comprising administering to the patient an agent suitable for inhibiting fungal secretion of siderophores. The method is particularly useful for immunocompromised patients susceptible to fungal infections caused by Aspergillus fumigatus, such as pulmonary aspergillosis. The invention also relates to diagnostic methods for detecting a biomarker indicative of likely A fumigatus infection in vivo, such as serum presence of TAF.

The invention relates to a preparation method for L-ornithine hydrochloride. The L-ornithine hydrochloride is produced through converting arginase. The method comprises the following technological steps: (1) preparing immobilized enzyme; (2) optimizing conversion conditions; and (3) extracting products and refining. Compared with the prior art, the invention has the advantages that the production cost is low, the production conditions are mild, the impurities in the conversion system are less, the technological steps are simple, the production and the operation are safe, the purity is high, one liter of solution contains 100-130g of L-ornithine hydrochloride, the yield is high, the conversion rate of arginine reaches more than 95 percent and the like.

A process for the fermentative preparation of L-ornithine using microorganisms characterized by an increased export of the amino acid.

The invention relates to an L-ornithine-L-aspartate preparation method. The preparation method comprises the following steps: dissolving anyone or a mixture of L-ornithine-alpha-ketoglutarate, L-ornithine citrate and L-ornithine malate in water, adding L-aspartic acid, adjusting the pH value of the obtained solution to 7.0-8.0, adding active carbon for decoloring, filtering, adding a proper amount of an organic solvent miscible with water to the obtained filtrate, carrying out stirring crystallization, filtering, and drying. The L-ornithine-L-aspartate preparation method has the advantages of high yield, good product quality (high content, low impurity contents and the like), low cost and the like.

The present invention relates to application of a novel signal peptide in L-arginine and its derivatives production from konjac powder, which belongs to the field of gene engineering, enzyme engineering and metabolism engineering. The present invention fused the signal peptide set forth in SEQ ID NO.1 with the β-mannanase of Bacillus subtilis CCTCC M 209200, and expressed the fused gene in the strain with high L-arginine yield. The recombinant strain Corynebacterium crenatum CGMCC 0890 / p MSPman had advantages on utilizing cheaper konjac powder as substrate, and after fermenting for 96 hours in a 5 L bioreactor, the L-arginine yield reached 45 g / L. Another two recombinant strains were constructed based on Corynebacterium crenatum CGMCC 0890 / pMSPman, and after fermenting for 96 hours in a 5 L bioreactor, the L-ornithine yield and L-citrulline reached 23.5 g / L and 26.3 g / L respectively.

The invention belongs to the field of pharmaceutical chemicals and relates to a preparation method for L-ornithine phenylacetate. The preparation method comprises the following steps of: mixing L-ornithine aqueous solution with phenylacetic acid solution; stirring and reacting the mixture; and crystallizing the obtained L-ornithine phenylacetate solution to separate out L-ornithine phenylacetate in the form of crystal. The preparation method is a one-step reaction, has a simple and gentle process, provides effective reference for the high purity and industrialization of the L-ornithine and phenylacetic acid, has a low toxic and side effect of the product, and ensures the safety of clinical medication. Compared with the prior art, the preparation method provided by the invention has low cost, high yield, and high product purity, and is suitable for industrial production.